Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis

Authors: Li-na Liu, Pei-yu Huang, Zhi-rui Lin, Li-juan Hu, Jian-zhong Liang, Man-zhi Li, Lin-quan Tang, Mu-sheng Zeng, Qian Zhong, Bo-hang Zeng

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

The aim of this study was to analyze the expression of protein tyrosine kinase 6 (PTK6) in nasopharyngeal carcinoma (NPC) samples, and to identify whether PTK6 can serve as a biomarker for the diagnosis and prognosis of NPC.

Methods

We used quantitative RT-PCR and Western blotting analysis to detect mRNA and protein expression of PTK6 in NPC cell lines and immortalized nasopharyngeal epithelial cell lines. 31 NPC and 16 non-tumorous nasopharyngeal mucosa biopsies were collected to detect the difference in the expression of mRNA level of PTK6 by quantitative RT-PCR. We also collected 178 NPC and 10 normal nasopharyngeal epithelial cases with clinical follow-up data to investigate the expression of PTK6 by immunohistochemistry staining (IHC). PTK6 overexpression on cell growth and colony formation ability were measured by the method of cell proliferation assay and colony formation assay.

Results

The expression of PTK6 was higher in most of NPC cell lines at both mRNA and protein levels than in immortalized nasopharyngeal epithelial cell lines (NPECs) induced by Bmi-1 (Bmi-1/NPEC1, and Bmi-1/NPEC2). The mRNA level of PTK6 was high in NPC biopsies compared to non-tumorous nasopharyngeal mucosa biopsies. IHC results showed the expression of PTK6 was significantly correlated to tumor size (P<0.001), clinical stage (P<0.001), and metastasis (P=0.016). The patients with high-expression of PTK6 had a significantly poor prognosis compared to those of low-expression (47.8% versus 80.0%, P<0.001), especially in the patients at the advanced stages (42.2% versus 79.1%, P<0.001). Multivariate analysis indicated that the level of PTK6 expression was an independent prognostic factor for the overall survival of patients with NPC (P <0.001). Overexpression of PTK6 in HNE1 cells enhanced the ability of cell proliferation and colony formation.

Conclusions

Our results suggest that high-expression of PTK6 is an independent factor for NPC patients and it might serve as a potential prognostic biomarker for patients with NPC.
Appendix
Available only for authorised users
Literature
1.
Titcomb CP: High incidence of nasopharyngeal carcinoma in Asia. J Insur Med. 2001, 33 (3): 235-238.PubMed
2.
Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM: Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012, 31 (4): 185-196. 10.5732/cjc.011.10328.PubMedCentralCrossRefPubMed
3.
4.
Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM, Goncalves FB: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003, 129 (7): 794-799. 10.1001/archotol.129.7.794.CrossRefPubMed
5.
Tao Q, Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007, 9 (12): 1-24.CrossRefPubMed
6.
Ma BB, Chan AT: Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005, 103 (1): 22-31. 10.1002/cncr.20768.CrossRefPubMed
7.
Tatsumi-Tamori A, Yoshizaki T, Miwa T, Furukawa M: Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol. 2000, 109 (12 Pt 1): 1125-1129.CrossRefPubMed
8.
Patel SG, Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005, 55 (4): 242-258. 10.3322/canjclin.55.4.242. quiz 261–242, 264CrossRefPubMed
9.
Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004, 350 (24): 2461-2470. 10.1056/NEJMoa032260.CrossRefPubMed
10.
Jiang LN, Dai LC, He JF, Chen YW, Ma ZH: Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006, 20 (2): 30-32.
11.
Liao Q, Zhao L, Chen X, Deng Y, Ding Y: Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma. Clin Exp Metastasis. 2008, 25 (4): 465-476. 10.1007/s10585-008-9152-8.PubMedCentralCrossRefPubMed
12.
Chua DT, Nicholls JM, Sham JS, Au GK: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004, 59 (1): 11-20. 10.1016/j.ijrobp.2003.10.038.CrossRefPubMed
13.
Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007, 13 (2 Pt 1): 508-514.CrossRefPubMed
14.
Liang FY, Sun W, Han P, Lu X, Lian YN, Huang XM: Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study. Chin J Cancer. 2012, 31 (3): 142-149. 10.5732/cjc.011.10279.PubMedCentralCrossRefPubMed
15.
Brauer PM, Tyner AL: Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta. 2010, 1806 (1): 66-73.PubMedCentralPubMed
16.
Serfas MS, Tyner AL: Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res. 2003, 13 (6–10): 409-419.PubMed
17.
Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, Gusterson BA, Crompton MR: Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene. 1994, 9 (8): 2383-2390.PubMed
18.
Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AH, Qin YR, Tsao SW: Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology. 2012, 143 (3): 675-686. 10.1053/j.gastro.2012.06.007. e671-612CrossRefPubMed
19.
Derry JJ, Prins GS, Ray V, Tyner AL: Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene. 2003, 22 (27): 4212-4220. 10.1038/sj.onc.1206465.CrossRefPubMed
20.
Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM, Tyner AL: BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999, 5 (7): 1767-1777.PubMed
21.
Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, Thomason A, Tyner AL: A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene. 1995, 10 (2): 349-357.PubMed
22.
Vasioukhin V, Tyner AL: A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci USA. 1997, 94 (26): 14477-14482. 10.1073/pnas.94.26.14477.PubMedCentralCrossRefPubMed
23.
Wang TC, Jee SH, Tsai TF, Huang YL, Tsai WL, Chen RH: Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. Br J Dermatol. 2005, 153 (2): 282-289. 10.1111/j.1365-2133.2005.06604.x.CrossRefPubMed
24.
Petro BJ, Tan RC, Tyner AL, Lingen MW, Watanabe K: Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol. 2004, 40 (10): 1040-1047. 10.1016/j.oraloncology.2004.05.010.CrossRefPubMed
25.
Kasprzycka M, Majewski M, Wang ZJ, Ptasznik A, Wysocka M, Zhang Q, Marzec M, Gimotty P, Crompton MR, Wasik MA: Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. Am J Pathol. 2006, 168 (5): 1631-1641. 10.2353/ajpath.2006.050521.PubMedCentralCrossRefPubMed
26.
Haegebarth A, Bie W, Yang R, Crawford SE, Vasioukhin V, Fuchs E, Tyner AL: Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol. 2006, 26 (13): 4949-4957. 10.1128/MCB.01901-05.PubMedCentralCrossRefPubMed
27.
Haegebarth A, Perekatt AO, Bie W, Gierut JJ, Tyner AL: Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology. 2009, 137 (3): 945-954. 10.1053/j.gastro.2009.05.054.PubMedCentralCrossRefPubMed
28.
Haegebarth A, Nunez R, Tyner AL: The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. Cell Cycle. 2005, 4 (9): 1239-1246. 10.4161/cc.4.9.1965.CrossRefPubMed
29.
Barker KT, Jackson LE, Crompton MR: BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene. 1997, 15 (7): 799-805. 10.1038/sj.onc.1201241.CrossRefPubMed
30.
Harvey AJ, Pennington CJ, Porter S, Burmi RS, Edwards DR, Court W, Eccles SA, Crompton MR: Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol. 2009, 175 (3): 1226-1234. 10.2353/ajpath.2009.080811.PubMedCentralCrossRefPubMed
31.
Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM: The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006, 5 (9): 1136-1141. 10.4161/cbt.5.9.2953.CrossRefPubMed
32.
Lin HS, Berry GJ, Fee WE, Terris DJ, Sun Z: Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004, 130 (3): 311-316. 10.1001/archotol.130.3.311.CrossRefPubMed
33.
Fan C, Zhao Y, Liu D, Zhang X, Wang E: Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance. Tumour Biol. 2011, 32 (5): 873-880. 10.1007/s13277-011-0188-z.CrossRefPubMed
34.
Easty DJ, Mitchell PJ, Patel K, Florenes VA, Spritz RA, Bennett DC: Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. International journal of cancer Journal international du cancer. 1997, 71 (6): 1061-1065. 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F.CrossRefPubMed
35.
Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva T, Tay LS, Loo HL, Foo P: Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 2007, 67 (23): 11368-11376. 10.1158/0008-5472.CAN-07-2703.CrossRefPubMed
36.
Kubo T, Kuroda Y, Kokubu A, Hosoda F, Arai Y, Hiraoka N, Hirohashi S, Shibata T: Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas. 2009, 38 (7): e200-e206. 10.1097/MPA.0b013e3181b8feb0.CrossRefPubMed
37.
Kubo T, Kuroda Y, Shimizu H, Kokubu A, Okada N, Hosoda F, Arai Y, Nakamura Y, Taniguchi H, Yanagihara K: Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis. 2009, 30 (11): 1857-1864. 10.1093/carcin/bgp206.CrossRefPubMed
38.
Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM, Tyner AL: Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci. 2010, 123 (Pt 2): 236-245.PubMedCentralCrossRefPubMed
39.
Ie Kim H, Lee ST: Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J Biochem. 2009, 146 (1): 133-139. 10.1093/jb/mvp050.CrossRefPubMed
40.
Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66 (12): 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRefPubMed
41.
Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009, 119 (12): 3626-3636. 10.1172/JCI39374.PubMedCentralCrossRefPubMed
42.
Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D: Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011, 71 (8): 3162-3172. 10.1158/0008-5472.CAN-10-3557.CrossRefPubMed
43.
Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL: Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011, 29 (34): 4516-4525. 10.1200/JCO.2010.33.7741.CrossRef
44.
Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, Guo Y, Huang YJ, Guan ZZ: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer. 2010, 10: 558-10.1186/1471-2407-10-558.PubMedCentralCrossRefPubMed
45.
Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, Xiao F, Fu X, Li J, Zhou B: Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol. 2012, 7: 2-10.1186/1748-717X-7-2.PubMedCentralCrossRefPubMed
46.
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998, 16 (4): 1310-1317.PubMed
47.
Ludyga N, Anastasov N, Gonzalez-Vasconcellos I, Ram M, Hofler H, Aubele M: Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer. Mol Biosyst. 2011, 7 (5): 1603-1612. 10.1039/c0mb00286k.CrossRefPubMed
48.
Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA: Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 2012, 3 (1–2): 14-25.PubMedCentralCrossRefPubMed
49.
Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365 (9476): 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed
50.
Razak AR, Siu LL, Liu FF, Ito E, O’Sullivan B, Chan K: Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010, 46 (11): 1967-1978. 10.1016/j.ejca.2010.04.004.CrossRefPubMed
51.
Gao J, Zhang HY, Xia YF:Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013, 34 (1): 39-45. 10.1007/s13277-012-0508-y.CrossRefPubMed
52.
Haegebarth A, Heap D, Bie W, Derry JJ, Richard S, Tyner AL: The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem. 2004, 279 (52): 54398-54404. 10.1074/jbc.M409579200.CrossRefPubMed
53.
Ostrander JH, Daniel AR, Lange CA: Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol. 2010, 10 (6): 662-669. 10.1016/j.coph.2010.08.007.PubMedCentralCrossRefPubMed
54.
Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM: PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007, 96 (5): 801-807. 10.1038/sj.bjc.6603613.PubMedCentralCrossRefPubMed
55.
Aubele M, Walch AK, Ludyga N, Braselmann H, Atkinson MJ, Luber B, Auer G, Tapio S, Cooke T, Bartlett JM: Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br J Cancer. 2008, 99 (7): 1089-1095. 10.1038/sj.bjc.6604660.PubMedCentralCrossRefPubMed
56.
Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML, Settleman J, Chen RH: Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res. 2008, 68 (19): 7779-7787. 10.1158/0008-5472.CAN-08-0997.CrossRefPubMed
57.
Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT: Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma–a prospective study. Head Neck. 2003, 25 (10): 864-872. 10.1002/hed.10307.CrossRefPubMed
58.
Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, Xu J: Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol. 2012, 29 (1): 263-271. 10.1007/s12032-010-9782-y.CrossRefPubMed
59.
Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH: Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol. 2004, 24 (24): 10558-10572. 10.1128/MCB.24.24.10558-10572.2004.PubMedCentralCrossRefPubMed
60.
Lukong KE, Richard S: Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell Signal. 2008, 20 (2): 432-442. 10.1016/j.cellsig.2007.11.003.CrossRefPubMed
61.
Castro NE, Lange CA: Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res. 2010, 12 (4): R60-10.1186/bcr2622.PubMedCentralCrossRefPubMed
62.
Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002, 62 (2): 589-596.PubMed
63.
Sun R, Zhang Q, Guo L, Chen MY, Sun Y, Cao B, Sun J: HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells. Oncol Lett. 2012, 3 (5): 1124-1128.PubMedCentralPubMed
64.
Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B: Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 2010, 17 (7): 1927-1936. 10.1245/s10434-010-0922-6.CrossRefPubMed
Metadata
Title
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis
Authors
Li-na Liu
Pei-yu Huang
Zhi-rui Lin
Li-juan Hu
Jian-zhong Liang
Man-zhi Li
Lin-quan Tang
Mu-sheng Zeng
Qian Zhong
Bo-hang Zeng
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-140

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma

Research

Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery

Research

Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial

Research

The role of globular heads of the C1q receptor in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis is associated with p38 MAPK/JNK activation

Research

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival

Research

Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits